Scarica l'app Stockscreener
20.33
2.47%
0.4671
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché APLS Giù?
Forum
Previsione
Precedente Chiudi:
$19.86
Aprire:
$20.09
Volume 24 ore:
653.93K
Relative Volume:
0.24
Capitalizzazione di mercato:
$2.60B
Reddito:
$715.22M
Utile/perdita netta:
$-250.10M
Rapporto P/E:
-10.01
EPS:
-2.03
Flusso di cassa netto:
$-205.58M
1 W Prestazione:
-5.96%
1M Prestazione:
-9.79%
6M Prestazione:
-27.65%
1 anno Prestazione:
-21.73%
Intervallo 1D:
$19.83
$20.80
Intervallo di 1 settimana:
$19.55
$21.30
Portata 52W:
$16.10
$30.48
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Nome
Apellis Pharmaceuticals Inc
Settore
Industria
Telefono
617-977-5700
Indirizzo
100 FIFTH AVENUE, WALTHAM, KY
Compare APLS vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
20.33 | 2.54B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.00 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
763.24 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
724.48 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
293.38 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Iniziato | Barclays | Equal Weight |
| 2026-01-21 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-11-06 | Iniziato | Wolfe Research | Peer Perform |
| 2025-10-15 | Iniziato | Wells Fargo | Overweight |
| 2025-09-26 | Downgrade | Goldman | Neutral → Sell |
| 2025-05-09 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-05-09 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Downgrade | Goldman | Buy → Neutral |
| 2024-11-21 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-10-25 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-10-16 | Iniziato | William Blair | Outperform |
| 2024-05-31 | Iniziato | Piper Sandler | Neutral |
| 2024-02-05 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-12-14 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | Iniziato | Goldman | Buy |
| 2023-11-02 | Iniziato | Mizuho | Neutral |
| 2023-10-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-09-15 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | Reiterato | Citigroup | Buy |
| 2023-08-03 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-08-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-01-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-19 | Iniziato | H.C. Wainwright | Buy |
| 2022-06-17 | Ripresa | Stifel | Buy |
| 2022-04-14 | Downgrade | ROTH Capital | Neutral → Sell |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2021-11-29 | Downgrade | ROTH Capital | Buy → Neutral |
| 2021-09-10 | Reiterato | BMO Capital Markets | Outperform |
| 2021-09-10 | Reiterato | Credit Suisse | Neutral |
| 2021-09-10 | Reiterato | Needham | Buy |
| 2021-09-10 | Reiterato | Oppenheimer | Outperform |
| 2021-09-10 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-08-19 | Iniziato | Jefferies | Buy |
| 2021-08-19 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-16 | Iniziato | Goldman | Buy |
| 2020-11-19 | Iniziato | Needham | Buy |
| 2020-09-01 | Iniziato | Stifel | Buy |
| 2020-07-20 | Iniziato | ROTH Capital | Buy |
| 2020-06-17 | Iniziato | BTIG Research | Neutral |
| 2020-04-01 | Iniziato | Raymond James | Strong Buy |
| 2020-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-11 | Aggiornamento | Wedbush | Underperform → Neutral |
| 2020-01-07 | Iniziato | SVB Leerink | Mkt Perform |
| 2019-12-19 | Iniziato | BofA/Merrill | Buy |
| 2019-11-22 | Iniziato | Wedbush | Underperform |
| 2019-11-05 | Iniziato | Credit Suisse | Neutral |
| 2019-08-01 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-07-30 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-04-12 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | Iniziato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Apellis Pharmaceuticals Inc Borsa (APLS) Ultime notizie
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $20.00 at Mizuho - MarketBeat
APLS: Mizuho Maintains Rating, Raises Price Target | APLS Stock News - GuruFocus
Assessing Apellis Pharmaceuticals: Insights From 11 Financial Analysts - Benzinga
Update Recap: Will Apellis Pharmaceuticals Inc benefit from geopolitical trendsMarket Performance Summary & Daily Technical Forecast Reports - baoquankhu1.vn
Apellis Pharmaceuticals (APLS) director receives new stock options and RSUs - Stock Titan
Apellis (APLS) director Mikael Dolsten submits initial Form 3 insider filing - Stock Titan
Apellis Pharmaceuticals (APLS) Stock Analysis: Exploring a 62.73% Upside Potential in Biotech - DirectorsTalk Interviews
Apellis Pharmaceuticals Details SYFOVRE, EMPAVELI Growth Plans and FcRn Gene-Editing Push at TD Cowen Conf. - MarketBeat
Apellis adds former Pfizer research chief to board - Investing.com
Apellis Pharmaceuticals appoints Mikael Dolsten to board of directors - Investing.com Australia
Apellis Pharmaceuticals2026 Funding Rounds & List of Investors - Tracxn
Apellis Pharmaceuticals, Inc. $APLS Shares Sold by Vanguard Group Inc. - MarketBeat
Apellis Pharmaceuticals Adds Mikael Dolsten to Board - TipRanks
Apellis adds former Pfizer research chief to board By Investing.com - Investing.com UK
Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors - Bitget
Mikael Dolsten joins Apellis Board as Class I director - TradingView
Mikael Dolsten joins Apellis (NASDAQ: APLS) board with equity grants - Stock Titan
Apellis Pharmaceuticals, Inc. Appoints Mikael Dolsten to Board of Directors, Effective March 1, 2026 - marketscreener.com
A Look At Apellis Pharmaceuticals (APLS) Valuation After 2025 Results And Softer Syfovre Growth Outlook - Sahm
Apellis Pharmaceuticals (NASDAQ:APLS) Lowered to Sell Rating by Wall Street Zen - MarketBeat
HC Wainwright Issues Optimistic Outlook for APLS Earnings - MarketBeat
Assessing Apellis Pharmaceuticals (APLS) Valuation After Prolonged Share Price Weakness - Yahoo Finance
Apellis (APLS) Q4 2025 Earnings Call Transcript - AOL.com
Analysts Issue Forecasts for APLS FY2030 Earnings - MarketBeat
Apellis price target lowered to $18 from $20 at Wedbush - Yahoo Finance
Apellis Pharmaceuticals Experiences Revision in Stock Evaluation Amidst Market Challenges - Markets Mojo
Apellis Profitability And Trial Progress Raise Questions On Valuation Gap - Sahm
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million - AOL.com
S&E In Brief: Commercial Updates From The SMID Cap Universe - Citeline News & Insights
RBC Capital Adjusts Price Target for Apellis Pharmaceuticals (AP - GuruFocus
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Cut to $44.00 by Analysts at Citigroup - MarketBeat
APLS: Citigroup Maintains Rating, Lowers Price Target to $44.00 - GuruFocus
Mizuho Securities Adjusts Apellis Pharmaceuticals PT to $20 From $19, Maintains Neutral Rating - marketscreener.com
Royal Bank Of Canada Lowers Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $21.00 - MarketBeat
Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y - Yahoo Finance
Why Apellis Pharmaceuticals Stock Is Under Pressure - TipRanks
RBC Capital Adjusts Apellis Pharmaceuticals PT to $21 From $22, Maintains Sector Perform Rating - marketscreener.com
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Lowered to $18.00 at Wedbush - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
APLS: Analyst Wedbush Lowers Price Target to $18 While Maintaini - GuruFocus
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q4 2025 Earnings Call Transcript - Insider Monkey
H.C. Wainwright raises Apellis stock price target on Syfovre outlook - Investing.com Australia
HC Wainwright & Co. Raises Price Target for APLS to $48.00 | APLS Stock News - GuruFocus
Apellis Pharmaceuticals Inc (APLS) Q4 2025 Earnings Call Highlig - GuruFocus
Decoding Apellis Pharmaceuticals Inc (APLS): A Strategic SWOT In - GuruFocus
Apellis Pharmaceuticals, Inc. (APLS) Stock Analysis: Exploring A 51% Upside Potential - DirectorsTalk Interviews
APLS Technical Analysis & ETF Price Forecast - Intellectia AI
Apellis Pharmaceuticals (APLS) Profitability Shift Tests Bullish Narratives After Q4 Loss - simplywall.st
Apellis Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Apellis Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap DownTime to Sell? - MarketBeat
Apellis Pharmaceuticals Inc Azioni (APLS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.96%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):